Insider Selling: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells 65,000 Shares of Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at $1,315,763.07. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Thomas Gad also recently made the following trade(s):

• On Monday, September 16th, Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $12.97, for a total value of $389,100.00.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock opened at $14.31 on Wednesday. The company’s 50-day moving average is $12.70 and its 200-day moving average is $13.52. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.69 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The business had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period last year, the firm earned ($0.14) EPS. As a group, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently added to or reduced their stakes in YMAB. Campbell & CO Investment Adviser LLC bought a new position in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $562,000. Squarepoint Ops LLC raised its holdings in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after acquiring an additional 74,452 shares during the period. Millennium Management LLC raised its holdings in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after acquiring an additional 67,233 shares during the period. Dimensional Fund Advisors LP lifted its position in Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the last quarter. Finally, Boston Partners bought a new stake in shares of Y-mAbs Therapeutics during the first quarter worth approximately $556,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on YMAB. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They set a “buy” rating and a $21.00 price objective for the company. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.